MedTrace Logo

ALIVE Expended Access - Clinical Study

NCT05710042 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-04-10

No results posted yet for this study

Summary

A prospective, multi-center, single-arm study. This study will enroll a maximum of 35 subjects treated with the Revivent TC System.

Conditions

Interventions

DEVICE

Revivent TC System

The Revivent TC System is indicated for patients suffering from symptomatic heart failure referred for treatment of left ventricular antero-septal aneurysms/scars that are contiguous and includes both anterior and septal components.

Sponsors & Collaborators

  • BioVentrix

    lead INDUSTRY

Principal Investigators

  • Gregg W Stone, MD · Icahn School of Medicine at Mount Sinai, New York, NY

  • Jerry Estep, MD · Cleveland Clinic Florida, Weston, FL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05710042 on ClinicalTrials.gov